UK biotech managed to attract a record-breaking £2.2bn in investment last year according to a BioIndustry Association (BIA) report.
The news essentially means that British firms were able to capture 40% of the venture capital funding that went out to the whole of Europe.
2017 saw British biotech raise about £1bn less than 2018 demonstrating that global investors very much still want to be a part of the United Kingdom’s fast-growing biotech agencies.
Just one example of booming biotech is IXICO – a neuroscience company which is venturing in the search for breakthrough treatments for brain illnesses including Parkinson’s, Huntington’s, multiple sclerosis, and Alzheimer’s – the latter of which has brought nothing but false promises and dashed hopes.
The two highest investments in monetary terms went to Orchard Therapeutics and Oxford Nanopore Technologies. Oxford Nanopore Technologies has produced a range of real-time low-cost DNA sequencing devices, of which the smallest weighs just 100g and plugs into a laptop and has been utilised to answer questions in clinical research on farms, food production factories, and even on the International Space Station.
The report outlined a few trends stating that “the number of sources of funding for UK drug discovery is expanding” and that US private investors were increasingly confident in investing in private British companies.
Furthermore it was noted that U.K. companies are playing the role of ‘acquirer’ as much as ‘acquired’ when it came to merger and acquisitions.